Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous BT088 hepatitis B immunoglobulin prophylaxis in liver transplant recipients
2008-007625-39Phase 3Terminated
- Sponsor
- Biotest AG
- Start
- Dec 2008
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Fovepta in hepatitis B (HBV), Hepatitis B virus reinfection after liver transplantation (rHBV) and Hepatitis B reactivation (HBVr), sponsored by Biotest AG. Primary endpoint: Safety of subcutaneous BT088. Started Dec 2008; status: terminated.
02
Drugs
Fovepta
03
Conditions
hepatitis B (HBV)Hepatitis B virus reinfection after liver transplantation (rHBV)Hepatitis B reactivation (HBVr)
Beyond the preview
Go deeper on 2008-007625-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007625-39.